Evonik Evonik

X

Find the latest Drugs in Development and Pipeline Prospector News of XPhyto.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
XPhyto
Canada Flag
Country
Country
Canada
Address
Address
Suite 1500 – 1055 W Georgia Street / Vancouver, BC V6E 4N7 / Canada
Telephone
Telephone
+1-780-818-6422
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Rotigotine is non-ergoline dopamine agonist approved for treatment of Parkinson’s disease and restless legs syndrome.Active pharmaceutical ingredient is not well absorbed via oral delivery and is formulated as a once-daily TDS patch to increase bioavailability.


Lead Product(s): Rotigotine

Therapeutic Area: Neurology Product Name: ROV045

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 18, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The company will use net proceeds of the financing to fund its research, development and commercialization activities for its lead Rotigotine and other pipeline candidates and for general working capital.


Lead Product(s): Rotigotine

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $3.6 million Upfront Cash: Undisclosed

Deal Type: Financing September 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The Company will use net proceeds of the placement to fund its research, development and commercialization activities especially for it's lead rotigotine and for general working capital.


Lead Product(s): Rotigotine

Therapeutic Area: Neurology Product Name: ROV045

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $1.8 million Upfront Cash: Undisclosed

Deal Type: Private Placement August 31, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The programs include in-vitro study of thin film delivery of cannabigerol and quercetin for potential anti-bacterial and anti-viral treatments as well as development of point-of-care sensor-film.


Lead Product(s): Cannabigerol

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY